Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9937593 | 0.87 | HTT (0.66) | MAPTGAAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL18797038 | 0.85 | MEN1 (0.53) | MAPTGAAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL18797039 | 0.85 | MEN1 (0.53) | MAPTGAAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL11526803 | 0.85 | HTT (0.71) | MAPTGAAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL29780105 | 0.84 | ALDH1A1 (0.54) | MAPTGAAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL18822434 | 0.84 | ALDH1A1 (0.54) | MAPTGAAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL2935107 | 0.83 | HTT (0.69) | MAPTGAAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL2979815 | 0.83 | MAPT (0.52) | MAPTGAAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL11511958 | 0.83 | ALDH1A1 (0.61) | MAPTGAAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL30483195 | 0.82 | ALDH1A1 (0.72) | MAPTHTTSMN1; SMN2MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276952-A1 | 4-AMINOPHENYL-THIAZOLE DERIVATIVES AND METHODS OF USE THEREOF | CYTEIR THERAPEUTICS INC (US) | 2025-09-04 | — | — | US | disclosed |
| WO-2023211942-A1 | 4-AMINOPHENYL-THIAZOLE DERIVATIVES AND METHODS OF USE THEREOF | CYTEIR THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-113582907-A | Preparation method of 5-hydrogen-benzo [ B ] carbazole derivative and derivative thereof | 陕西维世诺新材料有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20170002005-A1 | Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins | LIFE MOLECULAR IMAGING LIMITED (GB) | 2017-01-05 | — | — | US | disclosed |
| US-20170002005-A1 | Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins | LIFE MOLECULAR IMAGING LIMITED (GB) | 2017-01-05 | — | — | US | disclosed |
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| CN-101296911-A | Arylurea derivatives as modulators of chemokine receptor activity | NOVARTIS AG (CH) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | MAPT 4557/4885GAA 2978/4885HTT 4831/4885 |
| US-20250276952-A1 | 4-AMINOPHENYL-THIAZOLE DERIVATIVES AND METHODS OF USE THEREOF | ABAT, PYGB, MAPT | MAPT 3/4885GAA 72/4885HTT 56/4885 |
| US-20170002005-A1 | Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins | APP, BACE1, PSEN1 | MAPT 8/4885GAA 659/4885HTT 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.